Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1489609 | 1.00 | KDM4E (0.33) | KDM4EIRAK4ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL3642961 | 0.88 | KDM4E (0.39) | KDM4EIRAK4ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL3199228 | 0.78 | — | — | |
| SCHEMBL4761390 | 0.77 | — | — | |
| SCHEMBL1579432 | 0.76 | CARM1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL1461782 | 0.74 | — | — | |
| SCHEMBL1579038 | 0.74 | — | — | |
| SCHEMBL1579155 | 0.74 | — | — | |
| SCHEMBL3778248 | 0.74 | — | — | |
| SCHEMBL2094018 | 0.73 | PKM (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631570-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Abbott Laboratories (US) | 2006-03-08 | — | — | EP | claimed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | claimed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | BAYER INNOVATION GMBH (DE) | 2016-02-18 | — | — | US | disclosed |
| US-8975275-B2 | Use of chemotherapeutic agents | BAYER INNOVATION GMBH (DE) | 2015-03-10 | — | — | US | disclosed |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100330165-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | BAYER INNOVATION GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1408034-B1 | Use of Quinolone and Quinolizinone derivatives as chemotherapeutic agents | SCHULZ & SCHLIMBACH GBR (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1631570-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Abbott Laboratories (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-1408034-A1 | Use of Quinoline derivatives as antibacterial agents | Schulz & Schlimbach GbR (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1244434-B1 | USE OF CHEMOTHERAPEUTIC AGENTS | SCHULZ & SCHLIMBACH GBR (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | BAYER INNOVATION GMBH (DE) | 2003-03-06 | — | — | US | disclosed |
| EP-1244434-A2 | USE OF CHEMOTHERAPEUTIC AGENTS | Schulz, Hans-Herrmann (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001045679-A2 | USE OF CHEMOTHERAPEUTIC AGENTS FOR TOPICAL TREATMENT | SCHULZ HANS HERRMANN (DE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330165-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | TYMP, TP53, MSH2 | KDM4E 4471/4885IRAK4 1362/4885ALDH1A1 725/4885 |
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | NQO2, BROX, CYP4X1 | KDM4E 1901/4885IRAK4 1440/4885ALDH1A1 1931/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | KDM4E 4269/4885IRAK4 3054/4885ALDH1A1 292/4885 |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | TYMP, TP53, MSH2 | KDM4E 4471/4885IRAK4 1362/4885ALDH1A1 725/4885 |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | TYMP, TP53, MSH2 | KDM4E 4471/4885IRAK4 1362/4885ALDH1A1 725/4885 |
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | TYMP, TP53, MSH2 | KDM4E 4471/4885IRAK4 1362/4885ALDH1A1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.